InspireMD Reports Strong Q4 & FY25 Results, Guides for 45-65% Revenue Growth in 2026
NSPR sits 25% above its 52-week low of $1.51 on elevated volume (1.8× avg).
Summary
InspireMD announced strong Q4 and full-year 2025 financial results, including 62% Q4 revenue growth and a positive 2026 revenue guidance of 45-65%, signaling strong commercial momentum.
Key Events · Earnings and Guidance · NSPR
-
Q4 2025 Revenue Surges
Reported $3.1 million in revenue for the fourth quarter of 2025, a 62% increase year-over-year, driven by strong U.S. commercial launch of CGuard Prime.
-
Full Year 2025 Growth
Achieved $9.0 million in total revenue for the full year 2025, representing a 28% increase compared to the full year 2024.
-
Improved Gross Margin
Gross profit margin for Q4 2025 increased to 37.5% of revenue, up from 24.1% in Q4 2024, reflecting a favorable shift in sales mix towards higher-margin U.S. sales.
-
Positive 2026 Revenue Guidance
Management expects full-year 2026 revenue to be in the range of $13 million to $15 million, reflecting expected revenue growth of approximately 45% to 65% over 2025.
Analysis · NSPR · Industrial Applications And Services
InspireMD, a developer of carotid stent systems, reported robust financial results for Q4 and full-year 2025, driven by strong U.S. commercial traction for its CGuard Prime. The company achieved significant revenue growth and improved gross margins, while also providing an optimistic revenue outlook for 2026. This indicates successful execution of its commercial strategy and provides a clear growth trajectory for investors. The substantial cash position further supports its operational runway.
At the time of this filing, NSPR was trading at $1.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $75.8M. The 52-week trading range was $1.51 to $2.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.